Displaying 185 (all) recruiting clinical trials.
-
A Phase 3 Randomized Open-Label Three Arm Study of PF-06801591 in Combination with BCG (Induction With or Without Maintenance) Versus BCG (Induction and Maintenance) in Participants with HR BCG-Na ve NMIBC (B8011006)
The purpose of the study is to determine the safety and efficacy of PF-06801591 (an anti-PD-1 antibody) combined with Bacillus Calmette- Guerin (BCG) in patients ... -
Phase I/II study of dabrafenib trametinib and navitoclax in BRAF mutant melanoma (Phase I and II) and other solid tumors (Phase I only).
The purpose of the study is to determine the side effects and best dose of dabrafenib, trametinib, and navitoclax and to see how well they ... -
A Randomized Double-Blind Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
To determine if adding atezolizumab to a paclitaxel, trastuzumab, and pertuzumab improves survival. -
A Phase II study of Concurrent Chemoradiation plus Durvalumab (MEDI4736) followed by Surgery followed by Adjuvant Durvalumab (MEDI4736) in medically operable patients with surgically resectable Stage III (N2) Non-Small Cell Lung Cancer: A Hoosier Cancer Research Network Clinical Trial LUN 17-321
The purpose of the study is to determine the safety and efficacy of having Durvalumab with concurrent chemoradiation followed by surgery in patients with surgically ... -
Phase 1/1b Study to Evaluate the Safety & PK of JNJ-73841937 a Third Generation EGFR-TKI as Monotherapy or in Combinations With JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced NSCLC
The purpose of the study is to determine the safety and tolerability of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With ... -
A Phase 1 Open Label Multi-Arm Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid Tumors
This is a first-in-human (FIH), dose escalation, and dose finding trial to assess the safety and tolerability of MK-4830, both as monotherapy and as combination ... -
A Phase 1/2 Study Of REGN5093 In Patients With MET-Altered Advanced Non-Small Cell Lung Cancer
The main purpose of this study is to determine the safety, tolerability (how your body reacts to the drug), and effectiveness of investigational drug REGN5093 ... -
The Safety and Effectiveness of DuraSorb for Lower Pole Reinforcement in Patients Undergoing 2 Stage Breast Reconstruction
The purpose of this research is to test the safety and performance of DuraSorb® mesh when used to support your expander during 2-stage breast reconstruction ... -
A Phase 1 First-in-Human Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
The purpose of this study is to see if there are doses of JNJ-67571244 (also referred to as ‘study drug’) that are both safe and ... -
STAMP: Surgically Treated Adjuvant Merkel cell Carcinoma with Pembrolizumab a Phase III Trial (ECOG EA6174)
This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that ...